# OnCo record avc-203 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/avc-203/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "avc-203" ;
  schema:name "AVC-203"@en ;
  schema:alternateName "Allo-QuadCAR01-T"@en ;
  schema:description "AVC-203 is an experimental allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for relapsed/refractory B-cell malignancies and diffuse large B-cell lymphoma."@en ;
  schema:url <https://onco.cc/drugs/avc-203/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://avencell.com/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19-cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsed-ref/>, <https://avencell.com/pipeline/>, <https://clinicaltrials.gov/study/NCT07284433> ;
  onco:status "phase-1" ;
  onco:tag "pipeline" ;
  onco:modality "Allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/> ;
  onco:companies <https://onco.cc/companies/avencell-therapeutics/> .